Michael Bigham is the executive chairman of the board for Paratek Pharmaceuticals in Boston, Massachusetts.
Bigham first joined Paratek in 2014 as the chairman of the board of directors and CEO before stepping down as CEO in 2019 and taking on his current position.
Prior to Paratek, Bigham served as chairman and CEO of Avila Pharmaceuticals from 2007 to 2012. During his time there, Bigham served as the initial chairman and acting CEO, before hiring his replacement in 2008. He remained an active board member until the company was acquired by Celgene Corporation in 2012.
Bigham began his career in 1983 as a partner and co-head of healthcare and investment banking for Hambrecht & Quist, where he stayed until 1988. From 1988 to 1996, he worked as the executive vice president of operations and CFO of Gilead Sciences, where he was the eighth employee and the first vice president of the company. From 1996 to 2002, he served as CEO of Coulter Pharmaceuticals.
Bigham currently serves as an executive partner to Abingworth Management and a member of the board of directors of Adamas Pharmaceuticals and Frazier LifeSciences Acquisition Corporation.
He holds a B.S. from the University of Virginia, and earned his C.P.A prior to his M.B.A. from Stanford University.
What is Michael Bigham's net worth?
The estimated net worth of Michael Bigham is at least $2.98 million as of August 9th, 2023. Mr. Bigham owns 1,334,702 shares of Paratek Pharmaceuticals stock worth more than $2,976,385 as of September 27th. This net worth estimate does not reflect any other investments that Mr. Bigham may own. Additionally, Mr. Bigham receives a salary of $954,390.00 as Chairman at Paratek Pharmaceuticals. Learn More about Michael Bigham's net worth.
How old is Michael Bigham?
What is Michael Bigham's salary?
As the Chairman of Paratek Pharmaceuticals, Inc., Mr. Bigham earns $954,390.00 per year. The highest earning executive at Paratek Pharmaceuticals is Dr. Evan Loh FACC, FAHA, M.D., CEO & Director, who commands a salary of $1,140,000.00 per year. Learn More on Michael Bigham's salary.
How do I contact Michael Bigham?
Has Michael Bigham been buying or selling shares of Paratek Pharmaceuticals?
Michael Bigham has not been actively trading shares of Paratek Pharmaceuticals during the past quarter. Most recently, Michael Bigham sold 31,250 shares of the business's stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $2.20, for a transaction totalling $68,750.00. Following the completion of the sale, the chairman now directly owns 1,334,702 shares of the company's stock, valued at $2,936,344.40. Learn More on Michael Bigham's trading history.
Who are Paratek Pharmaceuticals' active insiders?
